United BioSource Corp. Named Preferred Oncology Clinical Research Partner by RainTree Oncology Services
Agreement Will Accelerate Clinical Trial Research and Improve Patient Outcomes
United BioSource Corp. (UBC), a subsidiary of Express Scripts ESRX, has been named the preferred oncology clinical research partner by RT Oncology Services Corp. (RainTree), the nation's leading community oncology alliance. The agreement seeks to improve patient care by accelerating clinical research in the U.S.
UBC is a market leader in the design and execution of peri- and post-approval clinical trials and clinical studies. As RainTree's preferred oncology clinical research partner, UBC will have access to patient data — under research protocol and with appropriate consent — from RainTree's alliance of oncologists throughout the U.S. UBC also will partner with RainTree to administer prospective and retrospective observational studies that will provide information about the safety and efficacy of medication in daily clinical use.
By standardizing processes within the RainTree community oncology setting, leveraging network wide electronic medical records and providing robust adherence to the principles of good clinical practices, this partnership drives faster completion of clinical research and provides patients in nonacademic treatment settings with access to the latest therapies.
Patrick Lindsay, president, UBC, said, "This partnership is at the core of UBC's distinction in supporting clinical development and optimizing the experience for the patient, physician, manufacturer and payer as new products are approved by regulators and introduced to the marketplace.
"We now have an excellent opportunity for community oncologists to gain experience with new therapies in the same setting where approximately 80 percent of cancer patients are treated. When these same medications are approved and released more broadly, physicians will already have important experience with these new therapies."
Jeff Patton, MD, chief medical officer of RainTree, said, "Data gathered by our alliance of oncologists can provide new insights into patterns of care, potential risk factors of new therapies and health-related quality of life, among other components essential to improving patient outcomes. UBC is the experienced partner we need to design and manage clinical research that optimizes the quality of the patient care we provide."
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
